§ 13,000,000 implants number is based on data of DES implants through Q4 2018. Comparative claim based on unit usage in U.S., Japan, China, India, top 5 Western Europe, and Korea. Other leading DES: BSX stents (Promus Element‡, Promus Element Plus‡, Promus Premier‡, SYNERGY‡); MDT stents (Resolute‡, Resolute Integrity‡, Resolute Onyx‡); Terumo stents (Nobori‡, Ultimaster‡); Biotronik stent (Orsiro‡); and Biosensors stent (BioMatrix‡). Data on file at Abbott.
* Tests performed by and data on file at Abbott:
- Enhanced design statement is in comparison to XIENCE Alpine™ Stent.
- Catheter performance crossability refers to testing performed on XIENCE Sierra™ Stent (3.0 x 18 mm) n = 5, SYNERGY‡ Stent(3.0 x 20 mm) n = 5, Resolute Onyx‡ Stent (3.0 x 18 mm) n = 5. Catheter performance crossability test measures average force to cross a challenging lesion model. Bench test data shows that XIENCE Sierra™ performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx‡ and SYNERGY‡ stents. Bench test results may not necessarily be indicative of clinical performance.
- Increased maximum expansion compared to other XIENCE™ Everolimus Eluting Coronary Stent Systems.
- Expanded treatment options with post-dilation expansion up to 5.5 mm (3.5-4.0 mm) and more complete size matrix for long tapered lesions. Side branch accessibility with workhorse diameter (3.0 x 18 mm) to treat bifurcations. Enhanced radial strength in workhorse sizes for highly calcified lesions (compared to previous generations).
- Ultra-low stent crimped profile of 0.0390" refers to XIENCE Sierra™ Stent profile size of (3.0 x 18 mm) n = 5, SYNERGY‡ Stent(3.0 x 20 mm) n = 5, Resolute Onyx‡ Stent (3.0 x 18 mm) n = 5.
- Shortening statement refers to testing performed on a 4.0 mm diameter stent deployed to 5.5 mm. XIENCE Sierra™ Stent (4.0 x 18 mm) n=5, Synergy‡ Stent (4.0 x 20 mm) n=5, Resolute Onyx‡ Stent (4.5 x 18 mm) n=5, Orsiro‡ Stent (4.0 x 18 mm) n=5.
- Increased maximum expansion compared to other XIENCE™ Everolimus Eluting Coronary Stent System.
- Retention testing is measured by dislodgement (lbf) average.
1. Serruys, PW et al. RESOLUTE All Comers Trial, 1-Yr Results Presentation, EuroPCR 2010.
2. Fajadet, PLATINUM PLUS, TCT 2012.
3. Smits P, et al. Abluminal biodegradable polymer BES vs. durable polymer EES (COMPARE II): a randomised, controlled, non-inferiority trial, The Lancet, dx.doi.org/10.1016/S0140-6736(12)61852-2, Jan 2013.
4. Saito, S et. al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial, European Heart Journal, May 2014.
5. Pilgrim, T; Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE); Lancet. 2014.
6. Natsuaki, M ; Two-year Outcome NEXT; ACC 2014.
7. Pilgrim, T; Device and Clinical Program Highlights: Orsiro; TCT 2015.
8. Windecker S, RESOLUTE All-Comers 5-Year Presentation, EuroPCR 2014.
9. Smits; The Final 5 Year Results From The COMPARE II trial; PCR 2016.
10. Stone, G . EXCEL: a prospective, randomized trial comparing everolimus-eluting stents and bypass graft surgery in selected patients with left main coronary artery disease. TCT 2018.
11. Teeuwen, K. et al. Randomized multicenter trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions (PRISON IV). JACC Cardiovasc Interv. 2017;10(2):133-143. doi:10.1016/j.jcin.2016.10.017.
12. Lam, M. Three year clinical outcome of patients with bifurcation treatment with second-generation Resolute and XIENCE V stents in the randomized TWENTE Trial. Am Heart J. 2015;169.
13. Kaul U, et al. Paclitaxel-eluting stents versus everolimus-eluting coronary stents in a diabetic population: two-year follow-up of the TUXEDO-India trial. EuroIntervention. 2017:13:1194-1201.
14. Sabaté M, et al. EXAMINATION Trial. Lancet. 2016;387;357-366.
15. Watanable, H. et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: STOPDAPT2 Trial. JAMA. 2019;321(24):2414-2427. doi:10.1001/jama.2019.8145.
16. Panchalingam V, et al. ASAIO J. 1993;39:M305-M309.